Share Email Print
cover

Proceedings Paper

High-performance mass spectrometry as a drug discovery tool: a high-throughput screening assay to identify RNA-binding ligands
Author(s): Kristin A. Sannes-Lowery; Jared J. Drader; Richard H. Griffey; Steven A. Hofstadler
Format Member Price Non-Member Price
PDF $14.40 $18.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

Fourier transform mass spectrometry (FTMS) is increasingly being used as a drug discovery tool. We describe the development of a parallel high-throughput screening (HTS) strategy to identify small molecules that bind RNA targets using FTMS as an alternative to classical high-throughput biological screening methods for combinatorial libraries. The Multitarget Affinity/Specificity Screening (MASS) assay takes advantage of the "intrinsic mass" label of each compound and target RNA by employing high resolution, high precision mass measurements. The ability to analyze complex mixtures allows large compound libraries to be screened in the presence of multiple RNA targets simultaneously. The identity of the small molecule(s) which bind, the RNA target to which it binds, the compound-specific binding affinity and the location of the binding site on the RNA can be determined in one set of rapid experiments. The MASS technology detects complexes with dissociation constants of < 5 mM, with high sensitivity.

Paper Details

Date Published: 16 April 2001
PDF: 10 pages
Proc. SPIE 4264, Genomics and Proteomics Technologies, (16 April 2001); doi: 10.1117/12.424586
Show Author Affiliations
Kristin A. Sannes-Lowery, Isis Pharmaceuticals, Inc. (United States)
Jared J. Drader, Isis Pharmaceuticals, Inc. (United States)
Richard H. Griffey, Isis Pharmaceuticals, Inc. (United States)
Steven A. Hofstadler, Isis Pharmaceuticals, Inc. (United States)


Published in SPIE Proceedings Vol. 4264:
Genomics and Proteomics Technologies
Ramesh Raghavachari; Weihong Tan, Editor(s)

© SPIE. Terms of Use
Back to Top